New methods for evaluation and treatment: Artery disease

Cost-effective Intervention for the Prevention of Cardiovascular Events

There has not been much evidence on the cost-effectiveness of approved interventions for the prevention of cardiovascular events among individuals with chronic coronary syndrome (stable coronary artery disease) or symptomatic peripheral artery disease at risk of cardiovascular complications in Finland. Soini et al. studied the cost-effectiveness, cost-utility, value of information, and economic value-added (EVA) of rivaroxaban when prescribed in combination with acetylsalicylic acid.

The study also included method developments:

  • EVA is a new method which combines both the monetary gain (benefit) and opportunity cost (risk) of intervention and can be presented as EVAC (economic value-added curve).
  • Future decisions of drug treatment initiation can be modelled by predicting e.g. the pharmaceutical market and costs of events for the decision year. Here, the prediction of future was beneficial for the intervention.
  • PICOSTEPS principle was also applied for the sensitivity analysis content development.

In line with the clinical rationale, the researchers set out to examine if intensified antithrombosis with rivaroxaban 2.5 mg twice daily in addition to acetylsalicylic acid 100 mg once daily (intervention) would be cost-effective compared to antithrombotic treatment with acetylsalicylic acid alone (comparator) in the comprehensive health economic evaluation setting. It was found that rivaroxaban was cost-effective and produced added value in the Finnish setting when used in addition to acetylsalicylic acid irrespective of the analyzed patient subgroup.

Link to the article: https://link.springer.com/article/10.1007/s12325-020-01398-8

More information: Erkki Soini




We are looking for Data Visualization Expert

Due to our business growth, we are looking for an experienced

DATA VISUALIZATION EXPERT

Your task will be to make social and health economic and data analysis results more accessible through designing and developing charting, graphical outputs as well as interactive data visualization interfaces to meet our clients’ goals. For instance, developing web-based interfaces for health economic models built with R or interactive real-world evidence reporting. Developing and improving the public visual profile of ESiOR would also be a part of your work.

We expect from you web and/or application development skills and artistic vision (i.e., a front-end developer with a focus in data and other visualization). This position emphasizes a need for an artistic eye and an innovative mind to conceptualize, design, and develop reusable graphics and data visualizations as well as technical knowledge for implementing these visualizations by building front-end web-based applications and graphics.

Requirements

  • Bachelor’s or equivalent Degree (Statistics, Mathematics, Data Science, Computer Science, Engineering, Arts, Design, Machine Learning, Artificial Intelligence or related field). Applicants with e.g. relevant polytechnic or vocational training, solid experience from the related field and other required qualifications are also welcomed to apply for the position. You may also have further, higher education.
  • Skills in the interactive data visualization and data interfaces.
  • Experience with web technologies, such as Javascript (e.g. d3.js), HTML or CSS etc.
  • Good problem solving and debugging skills.
  • Fluent written and oral communication in English. Knowledge in Finnish language is an advantage.
  • Experience with making complex data more accessible, consumable and actionable.
  • Good teamwork skills.

Valuable, but not essential

  • Experience in social, healthcare or pharmaceutical industry, health economics, hospital or market access
  • Skills in R and/or Python scripting
  • Knowledge with big data, data extraction, warehousing and analysis technologies such as Stata, SAS, SPSS, SQL, Azure, Hadoop and/or similar tools
  • Skills in data mining, deep learning, machine learning, artificial intelligence and/or such

 

We offer you an opportunity to be part of this growing business together with the top professionals of the field. With us you can develop your professional skills even further. We provide possibility for flexible and remote work, however good travel connections to the Finnish capital area and/or Kuopio are desirable.

Are you interested? You can call and ask further information: ESiOR Oy’s CEO Erkki Soini tel. 0400-533971 Monday 11.5. 10.00 – 17.00 and Monday 18.5. 11.00 – 18.00 and HRS Advisors consultant Seija Raesola tel. 040 775 6150.  Please, leave you application and CV together with your salary request no later than May 24th.




Two new PhDs to complement ESiOR expertise

Two of ESiOR’s employees, Senior Consultant Saku Väätäinen and Consultant, Market Access Manager Saara Huoponen, have completed their doctoral studies and received doctoral degrees in the field of Pharmacy.

———

Saku defended his doctoral dissertation on 22nd of February, 2020. The opponent for the public examination was Docent Arto Strandberg of University of Helsinki and custos Professor Janne Martikainen of University of Eastern Finland. Saku finished his studies and graduated in April 2020.

In his dissertation, ’Health Utility along the Diabetes Continuum, Examination of utility values in impaired glucose metabolism using pre-scored multi-attribute utility instruments’, Saku examined the relationship between impaired glucose metabolism and health-related quality of life (HRQoL) as part of larger Savitaipale Study.

Although the HRQoL effects of type 2 diabetes had been studied extensively previously, the effects of so called prediabetic stages, increased fasting glucose and impaired glucose metabolism, had not been examined previously.

Saku and his team’s publications were  first to show that impaired glucose metabolism and overall diabetes risk are associated with meaningfully impaired HRQoL. Findings can be used for health economic research and decision making, for instance in evaluating the cost-effectiveness of type 2 diabetes prevention interventions.

———-

Saara graduated earlier in December 2019. Saara defended her doctoral dissertation on 25th of October, 2019. The opponent for the public examination was Research Professor Hennamari Mikkola from the Social Insurance Institution of Finland and custos Professor Raimo K. Tuominen from the University of Helsinki.

In her dissertation, Saara evaluated the costs, effectiveness and cost-effectiveness of biological drugs in the treatment of rheumatoid arthritis and inflammatory bowel diseases.

The use of the biological drugs in the treatment of rheumatoid arthritis and inflammatory bowel diseases is causing significant health care costs. Health economic evaluations enable more efficient use of the limited health care resources. In the dissertation, Saara and her research group evaluated the cost-effectiveness of biological drugs in the Finnish health care setting using real-world data (RWD).

Health economic modelling based on the Finnish RWD did not show any meaningful differences in effectiveness between the examined biological drugs in rheumatoid arthritis patients who had been previously been treated with Tumour Necrosis Factor Alpha (TNF) inhibitors. However, TNF inhibitors produced most modelled QALYs with lowest costs, and, therefore, were the most cost-effective treatment option in the Finnish setting. In contrast, based on the systematic literature review, rituximab (a β cell inhibitor) was the most cost-effective biological drug for rheumatoid arthritis patients with an inadequate response to TNF inhibitor internationally.

Based on the systematic literature review, biological drugs appeared to be cost-effective in the treatment of the active and severe inflammatory bowel disease. Prospective Finnish RWD suggested that the impact that switching from the originator infliximab to a biosimilar had on HRQoL, disease activity or secondary healthcare costs (excluding the costs of infliximab) in the maintenance treatment of inflammatory bowel disease was not statistically significant 12 months after the switch from originator to a biosimilar.

 




Welcome! Christian and Roope

We are happy to welcome Dr. Christian Asseburg – Director, Evidence Generation – and Roope Metsä – Junior Consultant!

We are thrilled to have our friends and colleagues Christian Asseburg and Roope Metsä back at ESiOR!

Christian Asseburg (PhD, MSci) is a highly accomplished expert in modelling methods and meta-analyses and has previously worked in the United Kingdom, Germany, Iceland, Finland and Sweden. Now he is back and over 5 years of earlier employment continue after a few years in Sweden.

Roope Metsä did his health economics master’s training at ESiOR during summer 2019. As of October 2019, he is working as our junior consultant.

Additional information: Erkki Soini, Christian Asseburg, Roope Metsä




StopDia investment estimation

Web-based interactive estimation app: assessment of potential incidence and cost effects related to intervention​

​StopDia investment estimation application predicts and visualizes in simple example-type fashion the potential social return on investment (SROI, “saving potential”) related to action decreasing the incidence of type 2 diabetes. The saving potential assessment are used for e.g. in the planning and prediction of wellbeing and health promotion actions at the population level. ​

​The estimation app in Finnish is available from link.

Model works best with PC or laptop. Capacity is limited- please try again later if the model does not work.

Additional information: Erkki Soini​




eHealth2019: Five presentations

eHealth2019: Five presentations

We take part in eHealth2019 – International Conference 2019 & The 24th Finnish National Conference on Telemedicine and eHealth “Data-Driven Health” in Kuopio 2-3.4.2019.

Welcome to discuss health technology assessment and evaluation of social and health care services (stand 2) as well as to follow our presentations:

  • Tietoaltaat: Data-analytiikan, tiedon tuotannon ja terveystaloustulosten hyödyntäjän aarreaitta?
  • Cost-benefit evaluation of digital HealthyWeightHub: Virtual Hospital 2.0.
  • Digitalized secondary care services for insulin-dependent diabetes patients – Predictive cost-benefit analysis of Virtual Hospital 2.0 digital care path.
  • Child placement costs and cost drivers: Isaacus Kuopio data lake project.
  • Cost-benefit predictions of the Virtual Hospital 2.0 digitalized secondary care path for women with endometriosis in Turku area and in Finland.

 

More information: Erkki Soini, Taru Hallinen, Saku Väätäinen




Welcome Tuomas Lundström

ESiOR Oy experience is increasing… We welcome the 12th member of our team.

Tuomas Lundström has joined our team as consultant and data scientist. Tuomas has background from psychology added with statistics know-how. His area of expertise includes R and Python programs, which makes our analytics expertise even stronger for the best of our clients.

Our knowledge and expertise provide best solutions to your challenges!

Additional information: Erkki Soini




Welcome Riikka Kettunen

ESiOR Oy’s Market Access expertise is increasing… Welcome, Riikka Kettunen!

Riikka Kettunen has joined ESiOR as a Market Access Manager on August 13th 2018. Riikka has unique experience. She has been a member of Pharmaceuticals Pricing Board, Pharmaceutical Officer at Social Insurance Institution and Market Access Specialist as well as Scientific Advisor in a pharmaceutical company. Riikka strengthens the already comprehensive experience of ESiOR for the benefit of our customers.

Our knowledge and expertise provide best solutions to your challenges!

Additional information: Erkki Soini, Akseli Kivioja




SHEOG: cost-effectiveness group @LinkedIn

Social and Health Economics and Outcomes Group (SHEOG) @LinkedIn https://www.linkedin.com/groups/8678341

You are welcome to join SHEOG! SHEOG @LinkedIn aims to

  • encourage discussion about economic evaluation and outcomes research in social and health care (SOHE),
  • inform members of events and recent publications related to the economic evaluation or outcomes of SOHE, and
  • serve as a discussion and contacting forum related to challenges and solutions confronted in the field of SOHE economic evaluation or outcomes.

SHEOG interests include but are not limited to SOHE assessment themes, methods, results, scientific articles, congresses, financing and development related to drugs, procedures, devices, processes, digitalization, analytics, modelling, artificial intelligence or other SOHE technologies.

Posts in English or Finnish. Thank you!

Additional information: Erkki Soini




Virtual hospital 2.0 and Isaacus: presentations March 15, 2018

Virtual Hospital 2.0 mid-assessment and Isaacus pre-production project results are presented as podiums in an international eHealth2018 congress

ESiOR takes part in the international eHealth congress and has two oral presentations on current and also internationally interesting projects:

  • Virtual hospital 2.0 – modelled cost-benefit assessment: Towards potential economic efficiency with digitalization and customer-responsive services.
  • Isaacus pre-production project: child protection process and placement decision.

Congress registration is still open, welcome! eHealth2018 – The 23 ISfTeH International Conference on Telemedicine and eHealth https://www.telemedicine.fi/images/pdf/kansalliset_seminaarit/2018/eHealth2018-flyer.pdf

Additional information: Erkki Soini, Saku Väätäinen or Taru Hallinen